

### AMENDMENTS TO THE CLAIMS

1. (Original) A method of treating human skin, comprising:  
determining a site on skin of a human patient in need of treatment; and  
topically applying to the site a composition comprising platelet-rich plasma and dermatologically acceptable carrier.
2. (Original) The method of claim 1, further comprising: rubbing the composition into the skin.
3. (Original) The method of claim 1, further comprising: allowing the composition to be absorbed into the skin wherein the composition further comprises a skin permeation enhancer.
4. (Original) The method of claim 1, wherein the site comprises facial skin.
5. (Original) The method of claim 4, wherein the platelet-rich plasma comprises platelets obtained from the patient being treated.
6. (Original) The method of claim 1, further comprising: repeating the topical application of the composition to the site about every 6 to 48 hours.
7. (Cancelled)
8. (Currently amended) A method, comprising:  
extracting blood from a patient;  
concentrating platelets from the blood;  
combining the platelets with a a skin permeation enhancer and a pharmaceutically acceptable carrier for topical application to skin, thereby forming a composition.
9. (Currently amended) The method of claim 8, wherein the patient to which the composition is applied is the same patient from which the blood is extracted, ~~and the composition further comprises a skin permeation enhancer and the carrier is for topical application to skin.~~
10. (Original) The method claim 8, wherein the carrier is an injectable carrier and is combined with a component chosen from collagen, cultured cells, and mixtures thereof.
- 11-13. (Cancelled)
14. (Original) A method of culturing cells, comprising:  
isolating cells from a patient;

**Int'l Appl. No. : PCT/US2004/043383**  
**Int'l filing date : December 23, 2004**

placing the cells on a medium comprising platelet-rich plasma; and  
allowing the cells to proliferate.

15. (Original) The method of claim 14, wherein the isolated cells are fibroblast cells.

16. (Original) The method of claim 14, wherein the cells are isolated from the same patient as the platelets of the platelet-rich plasma are obtained.

17. (Original) The method of claim 14, wherein the isolate cells are stem cells.

18-42. (Cancelled)

43. (Original) A formulation, comprising:

cells cultured in a medium comprising platelet releasate obtained from the same patient as the cells; and

a pharmaceutically acceptable carrier.

44. (Original) The formulation of claim 43, wherein the cells are human fibroblast cells and the carrier is an injectable carrier.

45. (Cancelled)